An observational study in Erythropoietic Protoporphyria (EPP) and X-Linked Porphyria (XLP), sponsored by Portal Therapeutics, Inc.. Recruiting at 19 sites in 9 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Portal Therapeutics, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Protoporphyria, Erythropoietic with a site in United States — 4 open to participants now, 4 under way, 2 of them phase 3. Protoporphyria, Erythropoietic · United States.
Among the 18 studies in Protoporphyria, Erythropoietic with a site in United States, this one is one of 2 that started in 2026, is one of 4 observational ones, and was the 16th registered.
29 studies on the registry are indexed under Protoporphyria, Erythropoietic; 5 are open to participants now.
Browse Protoporphyria, Erythropoietic studies →4 of the 18 studies in Protoporphyria, Erythropoietic with a site in United States are open now. Recruiting first, the newest first:
Portal Therapeutics, Inc. · Sites in United States
Ages 12+
The American Porphyrias Expert Collaborative · Sites in United States
Ages 1 min+
Disc Medicine, Inc · Sites in United States, Australia, Belgium and 8 more countries
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Protoporphyria, Erythropoietic studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 3 take children under 18; none take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 6
First in 2010; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 77 across the 13 interventional studies, 150 across the 4 observational. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 18 have an industry lead sponsor. The 10 most frequent:
Portal Therapeutics, Inc. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Portal Therapeutics, Inc. has 3 studies filed under Protoporphyria, Erythropoietic — fewer than ten, so there is no comparison to draw.
1 of the studies in Protoporphyria, Erythropoietic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07567131Portal Therapeutics, Inc.Observational Study of Adults and Adolescents With Erythropoietic Protoporphyria (EPP) and X-linked Porphyria (XLP) | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Protoporphyria, Erythropoietic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to collect information about the effects of EPP/XLP in adults and adolescents. This is an observational study in which participants will not receive any treatment. Study details include:
The study design and key inclusion criteria are focused on EPP/XLP and are inclusive of all potential participants, including those from underrepresented racial and ethnic populations. The sites and countries selected have diverse populations and the potential to enroll diverse participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Confirmed diagnosis of EPP or XLP as follows:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Plasma Protoporphyrin IX (PPIX) Levels Over Time
Plasma protoporphyrin IX (PPIX) concentrations measured at specified study visits.
Time frame: Screening; Baseline; Weeks 4, 8, 12, 16, 20, 24
Clinical History of Phototoxic Symptoms and Prodrome Timing
Medical history of EPP/XLP symptoms, including time to onset of prodromal sensations and occurrence of phototoxic reactions.
Time frame: Screening, Baseline, Weeks 4, 8, 12, 16, 20, 24
Skin Damage Manifestations
Skin damage manifestations associated with EPP/XLP, including swelling, erythema, and chronic skin changes.
Time frame: Screening, Baseline, Weeks 4, 8, 12, 16, 20, 24
Light Exposure and Phototoxic Reaction Data From Daily Diary
Daily recorded light exposure (including time spent outdoors), light dosimetry measurements, and occurrence of phototoxic reactions as captured in participant diaries.
Time frame: Screening, Baseline, Weeks 4, 8, 12, 16, 20, 24
Sunlight Exposure Required to Induce Prodromal Symptoms
Amount of sunlight exposure associated with onset of prodromal symptoms, along with corresponding plasma protoporphyrin IX (PPIX) levels.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20
Liver Function Test Results
Blood levels of liver function parameters (e.g., alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], bilirubin) and corresponding plasma protoporphyrin IX (PPIX) levels.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24
Plan to share: Yes — What may be shared: De-identified individual participant data (no direct identifiers) Who can access it: Qualified researchers with a scientifically sound research proposal Conditions for access: Submission and approval of a research proposal Execution of a data sharing agreement (DSA) Compliance with privacy regulations (e.g., GDPR, HIPAA as applicable) How it will be shared: Through a secure data access process managed by the sponsor or designated data-sharing platform Timing: Typically after study completion and/or publication of primary results Purpose: To support further research on EPP and XLP while protecting participant confidentiality
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Mar 2027, 10 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Protoporphyria, Erythropoietic →
Portal Therapeutics, Inc.